Ticagrelor: Positive, negative and misunderstood properties as a new antiplatelet agent - Steiner - 2013 - Clinical and Experimental Pharmacology and Physiology - Wiley Online Library
Ticagrelor for the treatment of atherosclerotic disease: insights from the PARTHENON clinical development program | Future Cardiology
Bioactivation and mechanism of action of clopidogrel, prasugrel, and... | Download Scientific Diagram
Ticagrelor use in Stroke Patients: Past, Present, and Future | VHRM
Ticagrelor: agonising over its mechanisms of action - ppt download
The Dogged Search for Cryptic Effects of Ticagrelor | Circulation
Ticagrelor in ACS—what does PLATO teach us? | Nature Reviews Cardiology
Mechanism of Action (MOA) | BRILINTA® (ticagrelor) tablets | For HCPs
Proposed Mechanism of... - Sultania Cardiovascular Sciences | Facebook
P2Y12 inhibitors
البورد العراقي للصيدلة السريرية - 🔺️P2Y12 receptor antagonists ➡️Ticlopidine, clopidogrel, prasugrel, ticagrelor and cangrelor are P2Y12 ADP receptor inhibitors that also block platelet aggregation but by a mechanism different from that of
Ticagrelor: Pharmacokinetics, Pharmacodynamics, Clinical Efficacy, and Safety - Dobesh - 2014 - Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy - Wiley Online Library
New antiplatelet agents : ready for clinical application?
How to manage prasugrel and ticagrelor in daily practice - European Journal of Internal Medicine
Update on novel P2Y12 inhibitors: Focus on Prasugrel, Ticagrelor, Cangrelor and Elinogrel
References in Effect of Clopidogrel vs Ticagrelor on Platelet Aggregation and Inflammation Markers After Percutaneous Coronary Intervention for ST-Elevation Myocardial Infarction - Canadian Journal of Cardiology
Ticagrelor versus clopidogrel in elective percutaneous coronary intervention (ALPHEUS): a randomised, open-label, phase 3b trial - The Lancet
JCM | Free Full-Text | New Antithrombotic Drugs in Acute Coronary Syndrome | HTML
Ticagrelor versus placebo for the reduction of vaso-occlusive crises in pediatric sickle cell disease: Rationale and design of a randomized, double-blind, parallel-group, multicenter phase 3 study (HESTIA3) - ScienceDirect
CME Evaluation with Post-activity Survey - ppt download
Ticagrelor: from discovery to Phase III clinical trial | Future Cardiology
Ticagrelor - toward more efficient platelet inhibition and beyon | TCRM
Premature Ticagrelor Discontinuation in Secondary Prevention of Atherosclerotic CVD: JACC Review Topic of the Week | Journal of the American College of Cardiology
Ticagrelor - Wikipedia
